LeonaBio’s Lead Product Candidate, Lasofoxifene, To Be Featured In Multiple Presentations At Dava Oncology’s 4th Summit On Breast Cancer
LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that its lead product candidate,
LeonaBio's medicine will be shown at a big cancer conference, which means doctors and scientists get to learn about it. When a company presents at important medical meetings, it shows they're moving forward, though it doesn't guarantee the medicine will work.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.